CSL Behring Archives -

Australian biotech group CSL has agreed a deal to acquire Swiss drugmaker Vifor Pharma in an all-cash deal

Australia’s CSL makes $11.7bn bid for Swiss pharma Vifor

https://pharmaphorum.com/news/australias-csl-makes-11-7bn-bid-for-swiss-pharma-vifor/

News/ News/ R&D

Trial sets up filings for uniQure’s haemophilia gene therapy

Phil Taylor CSL Behring, gene therapy, haemophilia B, uniQure 0 Comment

Dutch biotech uniQure and partner CSL Behring are planning to file for approval of their gene therapy for

Trial sets up filings for uniQure’s haemophilia gene therapy

https://pharmaphorum.com/news/trial-sets-up-filings-for-uniqures-haemophilia-gene-therapy/

News/ News/ Sales and Marketing/ Top stories

$2bn deal sees uniQure license haemophilia B gene therapy to CSL Behring

George Underwood CSL Behring, haemophilia B, uniQure 0 Comment

UniQure has signed a deal that could be worth over $2 billion with CSL Behring – giving the

$2bn deal sees uniQure license haemophilia B gene therapy to CSL Behring

https://pharmaphorum.com/news/2bn-deal-sees-uniqure-license-haemophilia-b-gene-therapy-to-csl-behring/

Digital/ News/ News

CSL, BrightInsight team up on digital health for rare diseases

Phil Taylor BrightInsight, CSL Behring, digital, rare disease 0 Comment

CSL Behring has signed a deal with US firm BrightInsight to develop digital health products to help patients

CSL, BrightInsight team up on digital health for rare diseases

https://pharmaphorum.com/news/csl-brightinsight-team-up-on-digital-health-for-rare-diseases/

News/ News/ R&D

Plasma firms join forces on “unbranded” coronavirus treatment

Phil Taylor coronavirus, CSL Behring, hyperimmune immunoglobulin, plasma, Takeda 0 Comment

A group of companies that specialise in plasma-derived drugs will pool their resources to try to develop a

Plasma firms join forces on “unbranded” coronavirus treatment

https://pharmaphorum.com/news/plasma-firms-join-forces-on-unbranded-coronavirus-treatment/

News/ News/ R&D

CSL accuses ex-exec, now at Pharming, of stealing trade secrets

Phil Taylor CSL Behring, hereditary angioedema, Pharming 0 Comment

CSL Behring has filed a lawsuit against a former employee, claiming he stole sensitive information with the intention

CSL accuses ex-exec, now at Pharming, of stealing trade secrets

https://pharmaphorum.com/news/csl-accuses-ex-exec-now-at-pharming-of-stealing-trade-secrets/

R&D/ Views & Analysis/ Views and analysis

Taking plasma from donor to patient

George Underwood CSL Behring, plasma 0 Comment

Lutz Bonacker from CSL Behring tells us about the unique aspects of working with plasma-derived medicines and how

Taking plasma from donor to patient

https://pharmaphorum.com/views-and-analysis/taking-plasma-from-donor-to-patient/

Market Access/ News/ News/ Top stories

CSL Behring lung drug would cost NHS £8m per patient, says NICE

Joy Persaud CSL Behring, NICE, Rare diseases, respiratory 0 Comment

NICE has rejected CSL Behring’s alpha1-proteinase inhibitor Respreeza for treating genetic emphysema in draft guidance, saying that it

CSL Behring lung drug would cost NHS £8m per patient, says NICE

https://pharmaphorum.com/news/csl-behring-lung-drug-would-cost-nhs-8m-per-patient-says-nice/

Sales and Marketing/ Views & Analysis/ Views and analysis

Could digital technology revolutionise pharma in 2018?

Richard Staines Astra Zeneca, CSL Behring, digital technology, Eyeforpharma Barcelona 2018, IQVIA, Janssen, Real World Evidence 0 Comment

This year’s eyeforpharma conference in Barcelona outlined how 2018 could be a turning point for the industry. As

Could digital technology revolutionise pharma in 2018?

https://pharmaphorum.com/views-and-analysis/digital-technology-revolutionise-pharma-2018/

Trending

CSL Behring

Login